New Products

PI3K/Akt/mTOR
Catalog No. Product Name Information Added
E2032 MOTS-c MOTS-c, a mitochondria-derived peptide (MDP), exerts antinociceptive and anti-inflammatory effects through activating AMPK pathway and inhibiting MAP kinases-c-fos signaling pathway. Apr 01 2022
E0956 MP07-66 MP07-66, a FTY720 analogue, is devoid of immunosuppressive effects and shows promising antitumor effects in chronic lymphocytic leukemia by disruption of the SET-PP2A complex leading to PP2A reactivation. Mar 28 2022
E1031 MK-8722

MK-8722 is a potent, direct, allosteric activator of all 12 mammalian pan-AMPK complexes.

Dec 08 2021
E0121 Parsaclisib (INCB050465)

Parsaclisib (INCB050465, INCB-50465, IBI376) is a potent and highly selective PI3Kδ(PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases.

Sep 01 2021
E0072 Indirubin-3′-oxime Indirubin-3′-oxime (IDR3O, I3O) is an indirubin analogue that shows favorable inhibitory activity targeting GSK-3β and CDKs. Indirubin-3′-oxime also inhibits JNKs with IC50s of 0.8 μM, 1.4 μM, and 1.0 μM for JNK1, JNK2, and JNK3, respectively. Indirubin-3′-oxime activates Wnt/β-catenin signaling and inhibits adipocyte differentiation and obesity. Aug 26 2021
E0115 MTI-31 MTI-31 (LXI-15029) is a novel mTORC1/mTORC2 inhibitor with Kd of 0.2 nM in mTOR binding assays and displays >5,000-fold selectivity over PIK3CA, PIK3CB and PIK3G. Aug 26 2021
S8668 Inavolisib (GDC-0077) Inavolisib (GDC-0077, RG6114, RO-7113755) is a potent selective inhibitor of PI3K alpha (PI3Kα) with an IC50 of 0.038 nM. GDC-0077 is >300-fold more selective for PI3K alpha over the other class I PI3K isoforms (beta, delta, and gamma) and >2000-fold more selective over PIK family members. GDC-0077 binds to the ATP binding site of PI3K and inhibits the phosphorylation of PIP2 to PIP3. Aug 03 2021
S8779 Parsaclisib (INCB050465) Hydrochloride Parsaclisib (INCB050465, IBI376) Hydrochloride is a potent and highly selective PI3Kδ(PI3K delta) inhibitor with an IC50 of 1 nM at 1 mM ATP in biochemical assay and approximately 20,000-fold selectivity for PI3Kα, PI3Kβ, PI3Kγ and 57 other kinases. Jul 23 2021
S9860 BC1618 BC1618 is an orally active Fbxo48 inhibitor that stimulates adenosine monophosphate (AMP)-activated protein kinase (Ampk)-dependent signaling. BC1618 promotes mitochondrial fission, facilitates autophagy and improves hepatic insulin sensitivity. May 24 2021
S6085 KY19382 (A3051) KY19382 (A3051) is a Wnt/β-catenin signalling activator through inhibitory effects on both CXXC5–DVL interaction and GSK3β activity with IC50s of 19 nM and 10 nM, respectively. May 08 2021
JAK/STAT
Catalog No. Product Name Information Added
E2398 STAT5-IN-2 STAT5-IN-2 inhibits the growth of acute and chronic myeloid leukemia cells and the phosphorylation and transcriptional activity of STAT5, but not STAT3, AKT, or Erk1/2 phosphorylation, with minimal effects on bone marrow stromal cells that play vital functions in the microenvironment of hematopoietic and leukemic cells. Jun 19 2022
S9920 GYY4137 GYY4137 is a novel, water-soluble hydrogen sulfide (H2S)–releasing molecule with vasodilator and antihypertensive activity. GYY4137 shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway. GYY4137 also shows anti-inflammatory activity. Oct 26 2021
S6789 JAK Inhibitor I (Pyridone 6) JAK Inhibitor I (Pyridone 6, CMP 6, Compound 6) is a pan-JAK inhibitor with IC50s of 1 nM, 1 nM, 5 nM and 15 nM for JAK2, TYK2, JAK3 and JAK1, respectively. Oct 11 2021
S3566 Cerdulatinib (PRT062070) Cerdulatinib (PRT062070, PRT2070) is an oral active, multi-targeted tyrosine kinase inhibitor with IC50 of 12 nM/6 nM/8 nM/0.5 nM and 32 nM for JAK1/JAK2/JAK3/TYK2 and Syk, respectively. Also inhibits 19 other tested kinases with IC50 less than 200 nM. Mar 04 2021
S9676 Ropsacitinib (PF-06826647) Ropsacitinib (PF-06826647, Tyk2-IN-8, compound 10) is a selective and orally administered inhibitor of tyrosine kinase 2 (TYK2) with IC50 of 17 nM for binding to TYK2 catalytically active JH1 domain. PF-06826647 (Tyk2-IN-8, compound 10) also inhibits JAK1 and JAK2 with IC50 of 383 nM and 74 nM, respectively. PF-06826647 (Tyk2-IN-8, compound 10) is used in the treatment of psoriasis (PSO). Aug 27 2020
S9664 Colivelin Colivelin (CLN) is a brain-penetrant neuroprotective peptide with potent long-term capacity against deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin is an activator of STAT3. Aug 20 2020
S0918 Ginkgolic acid C17:1 Ginkgolic acid C17:1 (GAC 17:1) inhibits constitutive activation of STAT3 through the abrogation of upstream JAK2 and Src. Ginkgolic acid C17:1 can induce the substantial expression of PTEN and SHP-1. Ginkgolic acid C17:1 induces apoptosis of tumor cells. Jul 26 2020
S0981 BD750 BD750 is an immunosuppressant and a dual inhibitor of JAK3 and STAT5 that inhibits IL-2-induced JAK3/STAT5-dependent T cell proliferation with IC50 of 1.5 μM and 1.1 μM for mouse and human T-cell proliferation, respectively. Jul 26 2020
S0818 STAT3-IN-1 STAT3-IN-1 (compound 7d) is an excellent, selective and orally active inhibitor of STAT3 with IC50 of 1.82 μM and 2.14 μM in HT29 and MDA-MB 231 cells, respectively. STAT3-IN-1 induces apoptosis of tumor cells. Jun 05 2020
S1050 TCS PIM-1 1 TCS PIM-1 1 (SC 204330) is a potent and selective inhibitor of ATP-competitive Pim-1 kianse with IC50 of 50 nM, shows good selectivity over Pim-2 and MEK1/MEK2 with IC50 > 20000 nM. May 07 2020
Cell Cycle
Catalog No. Product Name Information Added
E1157 Pan-RAS-IN-1 Pan-RAS-IN-1, a pan-Ras inhibitor, binds to KRasG12D-GppNHp with a Kd less than 20 μM in MST, ITC and NMR assays, also binds to Ras proteins and exhibits lethality in cells partially dependent on expression of Ras proteins. Jun 19 2022
E1071 ASP2453 ASP2453, a potent, selective and covalent KRAS G12C inhibitor, inhibits the Son of Sevenless (SOS)-mediated interaction between KRAS G12C and Raf with an IC50 of 40 nM. Jun 16 2022
E2400 1A-116 1A-116 is a Rac1 inhibitor, with antitumoral and antimetastatic effects in several types of cancer, such as breast cancer, prevents Rac1-regulated processes involved in the primary tumorigenesis and metastastic processes. Jun 16 2022
S8816 PF-06873600 PF-06873600 is an inhibitor of cyclin-dependent kinase 2 (CDK2), CDK4, and CDK6 with Ki values of 0.1, 1.2, and 0.1 nM, respectively, blocks the phosphorylation of retinoblastoma protein (RB1), and limits the proliferation of OVCAR-3 ovarian cancer cells with EC50s of 19 and 45 nM, respectively. Jun 14 2022
S2880 GW843682X GW 843682X is a PLK inhibitor for PLK1 and PLK3 with IC50 of 2.2 nM and 9.1 nM, respectively. Jun 14 2022
E1000 Zn-C3 ZN-c3 is an oral active, highly effective and selective Wee1 inhibitor with IC50 of 3.9 nM, which can be used in cancer research. May 23 2022
E1047 NAV-2729 NAV-2729, an inhibitor of Arf6 activation which directly binds to Arf6, also inhibits all Arf guanine nucleotide exchange factors (ArfGEFs) with a strongest effect against BRAG2 and Arf1 . May 12 2022
E0951 Dalpiciclib Dalpiciclib (SHR-6390), a highly selective, orally bioavailable CDK4/6 inhibitor with comparable potencies against CDK4 and CDK6, exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated tumor-suppressor retinoblastoma protein (Rb) and inducing G1 cell cycle arrest.  Mar 28 2022
S7002 Zotiraciclib Zotiraciclib (SB1317; TG02) is a novel small molecule potent CDK/JAK2/FLT3 inhibitor, emerged with potent CDK (IC50 against CDKs 1, 2 and 9 = 9, 5 and 3 nM, respectively), FLT3 (IC50 = 19 nM) and JAK2 (IC50 = 19 nM) potency. Mar 15 2022
E0647 (R)-CR8 trihydrochloride (R)-CR8 trihydrochloride, one of CR8 isomers, is a potent inhibitor CDK1/2/5/7/9 with antiproliferative effect and proapoptotic effect on CML cell lines. Mar 10 2022
DNA Damage
Catalog No. Product Name Information Added
E1136 SKLB-197 SKLB-197 exerts selectively inhibition against ataxia telangiectasia mutated and Rad3-related (ATR) kinase with IC50 of 0.013 μM, also displays potent antitumor activity against ATM-deficent tumors both in vitro and in vivo. Jun 19 2022
E0097 Mericitabine Mericitabine (RG 7128, R-7128, PSI 6130 diisobutyrate) is a nucleoside inhibitor of the HCV NS5B polymerase that acts as an RNA chain terminator and prevents elongation of RNA transcripts during replication. Jun 17 2022
E1057 M4076 M4076 is an ATP-competitive inhibitor of the Ataxia telangiectasia mutated (ATM) kinase with IC50 of 0.2 nM, which targets tumor cell survival and growth by inhibiting double-strand break (DSB) repair as well as checkpoint control. Jun 16 2022
E0510 Cidofovir hydrate Cidofovir hydrate is a selective inhibitor of viral DNA synthesis through the selective inhibition of viral DNA polymerase. Jun 16 2022
E1146 CHD1Li 6.11 CHD1Li 6.11, a potent oncogenic chromodomain helicase DNA binding protein 1 like (CHD1L) inhibitor and an orally bioavailable antitumor agent, shows the enzymatic inhibition of the catalytic CHD1L (cat-CHD1L) recombinant protein with IC50 of 3.3 µM, and significantly reduces the tumor volume of colorectal cancer (CRC) xenografts generated from isolated quasi mesenchymal cells (M-Phenotype).  May 16 2022
E0609 Methyl methanesulfonate Methyl methanesulfonate (MMS), a DNA alkylating agent, modifies both guanine (to 7-methylguanine) and adenine (to 3-methlyladenine) to cause base mispairing and replication blocks, respectively. Mar 11 2022
S8999 Exatecan Mesylate Exatecan Mesylate (DX-8951f) is a water-soluble and non-pro-drug analog of camptothecin and shows significant topoisomerase I inhibition with IC50 of 0.975 μg/ml. Jan 12 2022
S9875 AZD5305 AZD5305 is a highly selective and potent inhibitor of PARP1 with an IC50 of 3 nM in wild-type A549 lung cancer cells. AZD5305 shows no or minimal growth inhibitory effects in other cells (IC50s >10μM). Dec 22 2021
S9903 NRD167

NRD167 is a potent and selective SIRT5 inhibitor.

Sep 10 2021
S6984 Dianhydrogalactitol (VAL-083) Dianhydrogalactitol (VAL-083, Dianhydrodulcitol, Dulcitol Diepoxide) is a bi-functional alkylating agent that readily crosses the blood-brain barrier and creates N7 methylation on DNA. Dianhydrogalactitol shows antitumor activity. Jun 25 2021
TGF-beta/smad
Catalog No. Product Name Information Added
S7710 R-268712 R-268712 is a potent and selective inhibitor of ALK5 with an IC50 of 2.5 nM. Jun 16 2022
S3552 SIS3 SIS3 is a cell-permeable inhibitor of Smad3 that selectively inhibits TGF-β1-dependent Smad3 phosphorylation and Smad3-mediated cellular signaling. SIS3 reduces TGF-β1-induced type 1 procollagen expression and myofibroblast differentiation in normal dermal fibroblasts as well as scleroderma fibroblasts. Feb 25 2021
S7692 A-83-01 A-83-01 is a potent inhibitor of TGF-β type I receptor (ALK5-TD) with IC50 of 12 nM. A-83-01 also inhibits the transcription induced by activin/nodal type I receptor (ALK4-TD) and nodal type I receptor (ALK7-TD) with IC50 of 45 nM and 7.5 nM, respectively.Solutions are best fresh-prepared. Jun 03 2020
S0523 SB 4 SB 4 is a potent and selective agonist of bone morphogenetic protein 4 (BMP4) signaling with EC50 of 74 nM. SB 4 enhances canonical BMP signaling and activates SMAD-1/5/9 phosphorylation. Apr 22 2020
S0153 SJ000291942 SJ000291942 is a canonical bone morphogenetic proteins (BMP) signaling pathway activator. Apr 15 2020
S0069 VTX-27 VTX-27 (Compound 27) is a potent and selective inhibitor of protein kinase C θ (PKC θ) with Ki of 0.08 nM and 16 nM for PKC θ and PKC δ, respectively. Apr 13 2020
S2234 BIBF-0775 BIBF-0775 is a selective inhibitor of transforming growth factor β Receptor I (TGFβRI,Alk5) with an IC50 of 34nM. Mar 04 2020
S6654 SRI-011381 SRI-011381 is a novel agonist of the TGF-beta signaling pathway for treatment of Alzheimer's disease. Jan 08 2020
S9522 Valrubicin Valrubicin is a chemotherapy drug used to treat bladder cancer. Valrubicin is a chemotherapy agent, inhibits TPA- and PDBu-induced PKC activation with IC50s of 0.85 and 1.25 μM, respectively. Dec 18 2019
S6713 ITD-1 ITD-1 is a potent TGF-β inhibitor. It does not block the kinase activity of either type I (TGFBR1) or type II (TGFBR2) TGFβ receptors but potently blocks phosphorylation of the effector SMAD2/3 proteins induced by TGFβ2, and only minimally in response to Activin A. Nov 06 2019
GPCR & G Protein
Catalog No. Product Name Information Added
E0809 Timapiprant Sodium Timapiprant sodium (OC000459 sodium), a potent, selective, and orally active D prostanoid receptor 2 (DP2, also known as CRTH2) antagonist, potently displaces [3H]PGD2 from human recombinant DP2, rat recombinant DP2, and human native DP2 with Ki values of 13, 3 and 4 nM, respectively. Jun 14 2022
E2363 APD334 APD334 (Etrasimod ) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells. May 25 2022
E0395 Vercirnon Vercirnon (GSK1605786A, CCX-282, Traficet-EN), an orally bioavailable, selective, and potent antagonist of CCR9, is an equipotent inhibitor of CCL25-directed chemotaxis of both splice forms of CCR9. May 06 2022
E0458 RTICBM-189 RTICBM-189 is a potent, brain-penetrant allosteric modulator of the cannabinoid type-1 (CB1) receptor with a pIC50 of 7.54 in Ca2+ mobilization assay. Jan 27 2022
E0192 Maropitant citrate

Maropitant citrate is a novel neurokinin type-1 (NK1) receptor antagonist with anti-inflammatory and analgesic properties.

Jan 24 2022
E0356 MIPS521

MIPS521 is a positive allosteric modulator of the A1R that exhibits analgesic efficacy in rats in vivo.

Dec 14 2021
S7604 BX471

BX471 (ZK811752, BAY 865047, SH T 04268H) is a potent nonpeptide CC chemokine receptor-1 (CCR1) antagonist with Ki values of 1 nM and 5.5 nM in both MIP-1α and MCP-3 binding to CCR1-transfected HEK293 cells, respectively.

Dec 08 2021
P1092 Abaloparatide (BA058)

Abaloparatide (BA058, BIM-44058, ITM-058) is a novel 34-amino acid peptide selected to be a potent and selective activator of the parathyroid hormone receptor (PTH1R) signaling pathway with an IC50 of 0.117 nM in SOST analysis.

Dec 08 2021
S6694 Grapiprant (CJ-023,423) Grapiprant (CJ-023,423, AT-001, AAT-007, RQ-00000007, CJ-23423) is a novel selective EP4 Prostaglandin Receptor inhibitor with Ki of 20 nM and 13 nM for rat EP4 receptor and human EP4 receptor, respectively. Dec 08 2021
E0141 Bexagliflozin (EGT1442)

Bexagliflozin (EGT1442, EGT-0001442, THR-1442) is a potent and selective SGLT2 inhibitor with an IC50 of 2 nM.

Nov 18 2021
PTK
Catalog No. Product Name Information Added
S2733 AV-412(MP-412) AV-412 is a second-generation, orally bioavailable dual EGFR/HER2 tyrosine kinase inhibitor. Jun 21 2022
E0939 Insulin Degludec Insulin degludec is an acylated basal insulin with a unique mechanism of protracted absorption involving the formation of a depot of soluble multihexamer chains after subcutaneous injection, shows a very long duration of action, with a half-life exceeding 25 h in PK/PD studies. Jun 16 2022
E0814 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit with IC50 of 200 nM for human recombinant c-Kit, also inhibits PDGFRα/β with IC50s of 540/800 nM, Lyn with IC50 of 510 nM for LynB, and, to a lesser extent, FGFR3 and FAK. Jun 14 2022
E0822 AST-1306 AST-1306 (Allitinib) is an orally active and irreversible EGFR, ErbB2 and inhibitor with IC50s of 0.5, 3 and 0.8 nM, respectively. Jun 14 2022
E1113 GSK215 GSK215 is a potent and selective PROTAC focal adhesion kinase (FAK) degrader, which exerts FAK degradation in A549 non-small-cell lung cancer cells with DC50 of 1.3 nM by a strong time-dependence way and maximal degradation (Dmax) near the limit of the assay quantification (Dmax 99%). May 26 2022
S8422 BMX-IN-1 BMX-IN-1 is a selective, irreversible inhibitor of bone marrow tyrosine kinase on chromosome X (BMX) targeting cysteine 496 (Cys496) located at the ATP-binding site, with an IC50 of 138 nM for wild-type BMX, also potently inhibits the related Bruton’s tyrosine kinase (BTK) with an IC50 of 10.4 nM.  May 17 2022
E0958 ZX-29 ZX-29 is a potent and selective ALK inhibitor with an IC50s of 2.1, 1.3 and 3.9 nM for ALK, ALK L1196M and ALK G1202R mutations, respectively. Mar 28 2022
E0368 DZD9008 DZD9008 is an oral, potent, irreversible, wild type-selective EGFR inhibitor against EGFR or HER2 Exon20ins and other mutations with IC50 ranging from 0.4 nM to 2.1 nM for mutant EGFR. Dec 23 2021
E0142 XL092

XL092 (JUN04542) is an ATP-competitive inhibitor of multiple RTKs including MET, VEGFR2, AXL and MER, with IC50 values of 15 nM, 1.6 nM, 3.4 nM, and 7.2 nM in cell-based assays, respectively.

Nov 19 2021
S6764 Pamufetinib (TAS-115) Pamufetinib (TAS-115) is a highly potent c-Met and VEGFR dual inhibitor with IC50s of 30 nM and 32 nM for recombinant VEGFR2 and recombinant MET, respectively. Oct 26 2021
Epigenetics
Catalog No. Product Name Information Added
E1194 HDAC10-IN-1 HDAC10-IN-1 (10c), a nanomolar inhibitors of HDAC10 with high specificity, inhibits HDAC10 with high specificity over HDAC6 and with no significant impact on class I HDACs, with a IC50 of 20 nM on danio rerio HDAC10 (drHDAC10). Jun 16 2022
E1195 HDAC10-IN-2 HDAC10-IN-1 (13b), a nanomolar inhibitors of HDAC10 with high specificity, inhibits HDAC10 with high specificity over HDAC6 and with no significant impact on class I HDACs, with a IC50 of 58 nM on danio rerio HDAC10 (drHDAC10). Jun 16 2022
E1144 dBRD9 dBRD9 is a bifunctional molecule that links a small molecule that specifically binds to the bromodomain of BRD9 and another ligand that recruits the cereblon E3 ubiquitin ligase, potently and selectively degrades BRD9 with IC50 of 104 nM in MOLM-13 cells. Jun 16 2022
E1024 MRTX1719 MRTX1719 is a synthetic lethal inhibitor of the PRMT5/MTA complex and selectively inhibits PRMT5 activity in MTAP-deleted cells compared to MTAP-wild-type cells. Jun 16 2022
S9934 KA2507 KA2507, a potent, orally active and selective HDAC6 inhibitor with IC50 of 2.5 nM, shows antitumor activities and immune modulatory effects in preclinical models. Jun 16 2022
S9889 dCBP-1 dCBP-1 is a potent and selective heterobifunctional degrader of p300/CBP by hijacking the E3 ubiquitin ligase CRBN, also is exceptionally potent at killing multiple myeloma cells and can abolish the enhancer that drives MYC oncogene expression. May 12 2022
E1150 SIRT7 inhibitor 97491 SIRT7 inhibitor 97491, a potent SIRT7 inhibitor with an IC50 of 325 nM, reduces deacetylase activity of SIRT7 in a dose-dependent manner. SIRT7 inhibitor 97491 prevents tumor progression by increasing p53 stability through acetylation at K373/382. SIRT7 inhibitor 97491 promotes apoptosis through caspase pathway. May 11 2022
S7042 AZ505 AZ505 is a potent and selective inhibitor of SMYD2 with an IC50 of 0.12 μM. Mar 10 2022
E0499 4SC-203 4SC-203 (SC71710) is a multikinase inhibitor with potential antineoplastic activity. 4SC-203 selectively inhibits FMS-related tyrosine kinase 3 (FLT3/STK1), FLT3 mutated forms, and vascular endothelial growth factor receptors (VEGFRs). Feb 10 2022
E0449 SGC-SMARCA-BRDVIII

SGC-SMARCA-BRDVIII is a potent and selective SMARCA2/4 BRD inhibitor.

Jan 24 2022
NF-κB
Catalog No. Product Name Information Added
S5899 (R)-(-)-Ibuprofen (R)-(-)-Ibuprofen ((R)-Ibuprofen) inhibits the activation of NF-κB in response to T-cell stimulation with IC50 of 121.8 μM. R(-)-ibuprofen exerts anti-inflammatory and antinociceptive effects. May 06 2021
S4611 TCEP Hydrochloride TCEP (Tris(2-carboxyethyl)phosphine) hydrochloride, a non-thiol reducing agent, promotes NF-κB-DNA binding in a dose-related manner. Apr 07 2021
S3384 (E/Z)-IT-603 (E/Z)-IT-603 is a mixture of E-IT-603 and Z-IT-603. IT-603 is a NF-κB family member c-Rel inhibitor with an IC50 of 3 μM in electrophoretic mobility shift assay (EMSA). Dec 11 2020
S1321 Urolithin B Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα. Urolithin B suppresses the phosphorylation of JNK, ERK, and Akt, and enhances the phosphorylation of AMPK. Urolithin B is also a regulator of skeletal muscle mass. Nov 18 2020
S8922 TBK1/IKKε-IN-1(compound 1) TBK1/IKKε-IN-1 (compound 1) is a dual inhibitor of TANK-binding kinase 1 (TBK1) and IκB kinase-ε (IKKε/IKK-i) with IC50 of 1.0 nM and 5.6 nM for TBK1 and IKKε, respectively. TBK1/IKKε inhibition enhances response to PD-1 blockade, which effectively predicts tumor response in vivo. May 14 2020
S0507 CBL0137 CBL0137 (Curaxin-137) is an inhibitor of the histone chaperone FACT (facilitates chromatin transcription) that simultaneously suppresses NF-κB and activates p53 with EC50 of 0.47 μM and 0.37 μM, respectively. Apr 22 2020
S0425 TBK1/IKKε-IN-2 TBK1/IKKε-IN-2 (Ikk epsilon-in-1, IKKε-IN-1, MDK10496) is a dual inhibitor of TBK1 and IKKε. Apr 22 2020
S6671 SN50 SN50 (NF-κB SN50), a cell-permeable NF-κB inhibitory peptide, is composed of the signal peptide of Kaposi fibroblast growth factor.SN50 inhibits the activation of NF-κB and attenuates ventilator-induced lung injury. Mar 25 2020
S8935 BAY-985 BAY-985 is a potent and highly selective TBK1/IKKε inhibitor. BAY-985 shows high potency toward TBK1 (IC50 = 2 nM, low ATP assay; 30 nM, high ATP assay) and IKKε(IC50 = 2 nM), as well as high potency in the mechanistic pIRF3 assay (IC50 = 74 nM), and an antiproliferative effect on SK-MEL-2 cells (IC50 = 900 nM). Mar 25 2020
S8941 NIK SMI1 NIK SMI1 is a highly potent and selective NF-κB-inducing kinase (NIK) inhibitor with Ki of 0.23 nM for NIK-catalyzed hydrolysis of ATP to ADP. Mar 25 2020
Metabolism
Catalog No. Product Name Information Added
A2043 Evolocumab (anti-PCSK9) Evolocumab (anti-PCSK9) is a human monoclonal antibody that inhibits PCSK9. Evolocumab binds to the circulating PCSK9 protein, inhibiting it from binding to the LDLR. Evolocumab can be used for the research of hypercholesterolemia and atherosclerotic cardiovascular diseases. Jun 22 2022
S8046 GW7647 GW7647 is a potent PPARα agonist, with EC50s of 6 nM, 1.1 μM, and 6.2 μM for human PPARα, PPARγ and PPARδ, respectively. Jun 19 2022
E2829 Alkannin Alkannin is a potent and specific inhibitor of tumor-specific pyruvate kinase-M2 (PKM2), without inhibiting PKM1 and pyruvate kinase-L (PKL). Jun 19 2022
E1142 GSK2033 GSK2033 is a LXR antagonist with pIC50s of 7 and 7.4 for LXRα and LXRβ, respectively. Jun 19 2022
E2826 Hematein Hematein inhibits casein kinase II activity in a selective, dose-dependent and ATP non-competitive manner in vitro, with IC50 of 0.55 μM in the presence of 10 μM ATP. Jun 19 2022
E1189 TES-1025 TES-1025 is a potent and selective human α-amino-β-carboxymuconate-ε-semialdehyde decarboxylase (ACMSD) inhibitor with an IC50 of 13 nM. May 23 2022
E1147 VY-3-135 VY-3-135, a potent ACSS2 inhibitor with IC50 of 44 ± 3.85 nM, potently inhibits ACSS2 dependent fatty acid metabolism but has no effect on gene expression in tumors. May 12 2022
E1171 SBI-425 SBI-425, a potent, selective and oral bioavailable tissue-nonspecific alkaline phosphatase (TNAP) inhibitor, effectively inhibits TNAP in the vasculature, improving cardiovascular parameters and survival. May 11 2022
S8942 Suramin sodium salt Suramin sodium salt (Suramin hexasodium salt) is a reversible and competitive protein-tyrosine phosphatase (PTPases) inhibitor, also is the potent inhibitor of sirtuins, purified topoisomerase II and SARS-CoV-2 RNA-dependent RNA polymerase (RdRp). May 11 2022
S3529 Linerixibat Linerixibat (GSK 2330672, GSK 672), a highly potent, nonabsorbable inhibitor of apical sodium dependent bile acid transporter (ABST), also known as the ileal bile acid transporter (IBAT), is used to the treatment of cholestatic pruritus in primary biliary Cholangitis. The IC50 of human ASBT is 42 nM. Mar 10 2022
Proteases
Catalog No. Product Name Information Added
S8998 IACS-6274 IACS-6274 (IPN60090), is a potent, selective and orally active glutaminase inhibitor with potential antineoplastic and immunostimulating activities. Jun 23 2022
E1014 Upamostat (WX-671) Upamostat (WX-671), a novel serine protease urokinase (uPA) inhibitor by inhibiting the urokinase-type plasminogen activator (uPA) system. Mar 17 2022
E0134 L-Albizziin

L-albizziin (L-alpha-amino-beta-ureidopropionic acid) is a potent inhibitor of glutamase. L-albizziin interferes with the utilisation of L-glutamine by the Debaryomyces spp. enzyme probably in a competitive and reversible manner since L-albizziin is also a substrate of the enzyme.

Nov 18 2021
E0122 Gemigliptin

Gemigliptin (Zemiglo, LC15-0444) is a potent, selective and long-acting dipeptidyl peptidase 4 (DPP 4) inhibitor with a Ki of 7.25 nM. Gemigliptin shows at least >23,000-fold selectivity for DPP-4 over various proteases and peptidases, including DPP-8, DPP-9, and fibroblast activation protein (FAP)-α.

Sep 27 2021
S9896 JNJ-67856633

JNJ-67856633 (JNJ-6633) is a potent, selective, allosteric inhibitor of MALT1 protease.

Sep 23 2021
S9909 ARP 100 ARP 100 (MMP-2 Inhibitor III, Compound 10a) is a potent and selective inhibitor of MMP-2 with an IC50 of 12 nM and displays less inhibitory activity at MMP-9, MMP-3, MMP-1 and MMP-7 with IC50s of 200 nM, 4500 nM, >50,000 nM and >50,000 nM respectively. Sep 01 2021
E0073 CL-82198 CL-82198 is a selective, orally bioavailable MMP-13 inhibitor with an IC50 of 3.2 μM. Aug 26 2021
S5960 Dabigatran etexilate mesylate Dabigatran etexilate mesylate (Pradaxa, BIBR 1048MS, Dabigatran etexilate methanesulfonate) is an orally active prodrug of Dabigatran which is a reversible and selective, direct thrombin inhibitor (DTI). Dabigatran selectively and reversibly inhibits human thrombin with Ki of 4.5 nM and thrombin-induced platelet aggregation with IC50 of 10 nM. Apr 27 2021
S4432 Ixazomib Citrate (MLN9708) Ixazomib citrate (MLN9708, Ninlaro) is a prodrug of Ixazomib (MLN2238), which is a selective, orally bioavailable inhibitor of 20S proteasome that inhibits the chymotrypsin-like proteolytic (β5) site with IC50 of 3.4 nM and Ki of 0.93 nM, respectively. Ixazomib (MLN2238) also inhibits caspase-like (β1) and trypsin-like (β2) proteolytic sites with IC50 of 31 nM and 3500 nM, respectively. Apr 13 2021
S4426 Sacubitril hemicalcium salt Sacubitril (AHU-377) hemicalcium salt, a component of the heart failure medicine LCZ696, is a potent inhibitor of neprilysin (neutral endopeptidase, NEP). Mar 30 2021
Microbiology
Catalog No. Product Name Information Added
E1126 AFN-1252 AFN-1252 (Debio 1452) is a potent inhibitor of enoyl-acyl carrier protein reductase (FabI), inhibits all clinical isolates of Staphylococcus aureus and Staphylococcus epidermidis at concentrations of ≤0.12 μg/ml. Jun 19 2022
S1265 SQ109 SQ109 is a potent inhibitor of the trypomastigote form of the parasite, with IC50 for LLC-MK2 culture-derived trypomastigotes of 50±8 nM, targets MmpL3 (mycobacterial membrane protein large 3) in Mycobacterium tuberculosis. Jun 17 2022
E0749 Coumalic acid Coumalic acid is a valuable platform compound which can be prepared from malic acid, can be used in the flavours, fragrances and cosmetics industries, as polymer components, and as pharmaceutical scaffolds displaying anti-bronchial and -malarial activity. Jun 16 2022
E1131 S-217622 S-217622 (Ensitrelvir fumarate) is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor with IC50 of 13 nM. Jun 16 2022
E2812 Antimalarial agent 1 Antimalarial agent 1 is a potent antimalarial drug. Jun 16 2022
E0938 Brincidofovir Brincidofovir (CMX001), the lipid-conjugated prodrug of Cidofovir (HY-17438) with long-acting antiviral effect, shows activity against a broad spectrum of DNA viruses including cytomegalovirus (CMV), adenovirus (ADV), varicella zoster virus, herpes simplex virus, polyomaviruses, papillomaviruses, poxviruses, and mixed double-stranded DNA virus infections. Jun 16 2022
S9963 paquinimod Paquinimod (ABR 25757), a specific inhibitor of S100A8/A9, could rescue the pneumonia with substantial reduction of viral loads in SARS-CoV-2-infected mice. Jun 16 2022
E0815 Rilpivirine Hydrochloride Rilpivirine (TMC278), is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. Jun 14 2022
E0820 OX02983 OX02983 is a novel anthelmintic agent, actives against both egg and adult stages of Trichuris parasites, immobilising whipworm and reducing the ability of embryonated Trichuris muris eggs to establish infection in the mouse host. Jun 14 2022
E1111 VV116 VV116, a promising orally administered anti-SARS-CoV-2 nucleoside drug candidate, exerts functions by targeting the viral RNA-dependent RNA polymerase through its nucleoside triphosphate form with an IC50 of 0.67±0.24 μM. May 26 2022
Apoptosis
Catalog No. Product Name Information Added
S9736 ME-344 ME-344 directly targets the OXPHOS complex 1, a pathway involved in the production of ATP, in the mitochondria. Treatment of tumor cells with ME-344 as a single agent results in a rapid loss of ATP and cancer cell death.ME-344 results in inhibition of cell growth and viability in all the leukemia cell lines with IC50 values in the range of 70–260 nM. Jun 16 2022
E1139 DX3-213B DX3-213B is a highly potent, orally active oxidative phosphorylation (OXPHOS) complex I inhibitor with IC50 of 3.6 nM, and impairs ATP generation with IC50 of 11 nM. Jun 16 2022
E2028 Humanin (human) Humanin (human) (1-24-Protein humanin (human)), a small mitochondrial-derived cytoprotective polypeptide encoded by mtDNA, exhibits protective effects in several cell types against cellular stress conditions and apoptosis through regulating various signaling mechanisms, such as JAK/STAT pathway and interaction of BCL-2 family of protein. Apr 01 2022
S7274 HLY78 HLY78 inhibits apoptosis in tumor cells and embryonic cells caused by carbon ion radiation through activation of the Wnt/β-catenin pathway. Mar 17 2022
S8487 AP20187 AP20187 (B/B Homodimerizer) is a chemical inducer of dimerization that activates FKBP-Casp8. Dec 30 2021
A2035 Sintilimab (anti-PD-1) Sintilimab (anti-PD-1, IBI 308) is a fully human IgG4 monoclonal antibody that binds to PD-1 on the surface of T-cells, blocks the PD-1/PD-Ligand 1 (PD-L1) pathway, and reactivates T-cells to kill cancer cells. Dec 23 2021
E0301 Necrostatin-34 (Nec-34) Necrostatin-34 (Nec-34) is a small molecule inhibitor of RIPK1 kinase with an IC50 of 0.13 μM in L929 cells. Dec 22 2021
E0375 Ammonium ferric citrate Ammonium ferric citrate (Ferric ammonium citrate, Ammonium iron(III) citrate, Iron ammonium citrate, FerriSeltz) induces ferroptosis in non-small-cell lung carcinoma through the inhibition of GPX4-GSS/GSR-GGT axis activity. Dec 22 2021
E0314 JTE-607 Dihydrochloride

JTE-607 Dihydrochloride is a prodrug compound that is converted to an active form by ester hydrolysis. JTE-607 is a multiple cytokine production inhibitor that targets CPSF3 and inhibits pre-mRNA processing. JTE-607 inhibits tumor necrosis factor (TNF)-alpha, interleukin (IL)-1beta, IL-6, IL-8 and IL-10, from LPS-stimulated human PBMCs, with IC50 values of 11 nM, 5.9 nM, 8.8 nM, 7.3 nM and 9.1 nM, respectively.

Nov 30 2021
E1051 MRTX1133

MRTX1133 is a highly selective inhibitor of mutant KRAS G12D and can reversibly binds to the activated and inactivated KRAS G12D mutants and inhibit their activity. The specificity of MRTX1133 to KRAS G12D is more than 1000 times that of wild-type KRAS.

Nov 24 2021
MAPK
Catalog No. Product Name Information Added
E0526 sappanone A Sappanone A, a homoisoflavanone isolated from the heartwood of Caesalpinia sappan (Leguminosae), induces HO-1 expression by activating Nrf2 through the p38 MAPK pathway, suppresses LPS-induced NF-κB activation by suppressing the phosphorylation of RelA/p65 at Ser536, exerting its anti-inflammatory effect. Jun 20 2022
E2407 MK2-IN-1 hydrochloride MK2-IN-1 hydrochloride is a potent and selective MAPKAP-K2 (MK2) inhibitor with IC50 of 0.11 μM with a non-ATP competitive binding mode. Jun 20 2022
E2630 SKF-86002 SKF-86002 is an orally active p38 MAPK inhibitor, inhibits lipopolysaccharide (LPS)-stimulate human monocyte IL-1 and TNF-α production with IC50 of 1 μM, also inhibits lipoxygenase- and cyclooxygenase-mediated metabolism of arachidonic acid. Jun 20 2022
S0387 SB 242235 SB-242235 is a potent and selective p38 MAP kinase inhibitor, inhibits p38 MAP kinase induced by IL-1β with an IC50 of approximately 1.0 μM in primary human chondrocytes. Jun 19 2022
E2682 RPI-1 RPI-1 inhibits proliferation of human papillary thyroid carcinoma cell line TPC-1 by inducing accumulation of cells at the G2 cell cycle phase, abolishes Ret/Ptc1 tyrosine phosphorylation along with its binding to Shc and phospholipase Cg, also abolishes the activation of JNK2 and AKT. Jun 16 2022
P1106 D-JNKI-1 D-JNKI-1 (AM-111, XG-102) is a highly and cell-permeable peptide inhibitor of JNK. Jun 08 2022
E0404 Zapnometinib (PD0184264) Zapnometinib (PD0184264, ATR-002), an major active metabolite of CI-1040, is a novel MEK inhibitor with an IC50 of 5.7 nM. Dec 28 2021
S8224 PF-3644022

PF-3644022 is a potent freely reversible ATP-competitive inhibitor of MAPKAPK2 (MK2) with an Ki of 3 nM. PF-3644022 also potently inhibits TNFα production with an IC50 of 160 nM.

Nov 04 2021
S4484 Trametinib DMSO solvate Trametinib (GSK1120212, JTP-74057, Mekinist) DMSO solvate is a highly specific and potent MEK1/2 inhibitor with IC50 of 0.92 nM/1.8 nM in cell-free assay. Trametinib activates autophagy and induces apoptosis. Apr 07 2021
S8569 KO-947 KO-947 is a potent and selective inhibitor of ERK1/2 kinases. KO-947 blocks ERK signaling and proliferation of tumor cells exhibiting dysregulation of MAPK pathway signaling at low nanomolar concentrations. Dec 07 2020
Angiogenesis
Catalog No. Product Name Information Added
S7715 FIIN-3 FIIN-3 is an irreversible inhibitor of FGFR with an IC50 of 13.1, 21, 31.4, and 35.3 nM for FGFR1, FGFR2, FGFR3 and FGFR4, respectively. Jun 16 2022
E0187 N-hydroxymethyl succinimide   Apr 27 2022
E2145 Ornoprostil   Apr 15 2022
E0985 11(α)-methoxysaikosaponin F

11(α)-Methoxysaikosaponin F is a triterpenoid saponin isolated from <i>Bupleurum marginatum Wall.ex DC(ZYCH)</i>. 11(α)-Methoxysaikosaponin F has an IC50 of 387.7 nM with viability of hepatic stellate cells-T6 (HSCs-T6).

Mar 29 2022
E0995 Alpha-Ionone

Alpha-ionone  is a natural product found in <i>Camellia sinensis</i>, <i>Swertia japonica</i>, and other organisms.

Mar 29 2022
E2017 Deoxypodophyllotoxin

Deoxypodophyllotoxin (DPT) is a lignin separated from rhizomes of <i>Sinopodophullum hexandrum</i> with potent antimitotic, anti-inflammatory and antiviral activities.

Mar 29 2022
E0658 Asperulosidic acid

Asperulosidic Acid (ASPA), a bioactive iridoid glycoside, is extracted from the herbs of Hedyotis diffusa Willd. Asperulosidic Acid (ASPA) has anti-tumor, anti-oxidant, and anti-inflammatory activities. ASPA is related to the inhibition of inflammatory cytokines (TNF-α, IL-6) and mediators via suppression of the NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways.

Mar 08 2022
S9892 HM43239

HM43239 is a novel potent small molecule FLT3 inhibitor that selectively inhibits not only FLT3 wild type, ITD mutants or TKD mutations, but also FLT3 ITD/TKD double mutations. IC50s' of HM43239 against FLT3 WT, FLT3 ITD and FLT3 D835Y kinases are 1.1 nM, 1.8 nM and 1.0 nM, respectively.

Jan 24 2022
S9973 Flumatinib (HH-GV-678)

Flumatinib (HH-GV-678) is a novel inhibitor of Bcr-Abl with IC50 values of 1.2  nM, 307.6  nM and 665.5  nM for c-Abl, PDGFRβand c-Kit, respectively.

Jan 24 2022
S9825 Pirtobrutinib (LOXO-305)

Pirtobrutinib (LOXO-305, LY 3527727, RXC-005) is a highly selective, non-covalent, next generation BTK inhibitor with an IC50 of 5.69 nM in WT BTK HEK cells. Pirtobrutinib shows more than 300-fold selective for BTK over 98% of 370 other kinases.

Nov 18 2021
Stem Cell & Wnt
Catalog No. Product Name Information Added
S6699 Gigantol Gigantol is a bibenzyl component isolated from several medicinal orchids, which can inhibit Wnt/β-catenin pathway and has anti-tumor activity. Apr 06 2022
S6384 Smoothened Agonist (SAG)

Smoothened Agonist (SAG) is potent agonist of Smoothened (Smo). Smoothened Agonist induces firefly luciferase expression in Shh-LIGHT2 cells with an EC50 of 3 nM.

Nov 04 2021
E0033 IWP-4

IWP-4 is a potent Wnt/β-catenin signaling pathway inhibitor with an IC50 of 25 nM.

Sep 01 2021
S5992 Heparan Sulfate Heparan sulfate (HS, Heparitin sulfate, Alpha-idosane, HHS 5, N-Acetylheparan Sulfate, Suleparoid, Tavidan), a constituent of HS proteoglycans (HSPGs), is a linear polysaccharide present on the cell surface. Heparan sulfate influences the binding affinity of intestinal epithelium cells (IECs) to Wnt, thereby promoting activation of canonical Wnt signaling and facilitating regeneration of small intestinal crypts after epithelial injury. May 17 2021
S9828 WAY-262611 WAY-262611 (BML-WN110, Compound 5) is a beta-catenin (β-Catenin) agonist that increases bone formation rate with EC50 of 0.63 μM in TCF-Luciferase assay. WAY-262611 is also an inhibitor of dickkopf 1 (DKK1). May 06 2021
S6961 Foxy-5 Foxy-5, a Wnt-5a mimicking hexapeptide, is a WNT signalling pathway modulator potentially for the treatment of metastatic breast cancer, prostate cancer and colorectal cancer. Jan 11 2021
S2962 NP-G2-044 NP-G2-044 is a potent, orally active inhibitor of the actin-bundling activity of fascin with IC50 of ~0.2 μM. NP-G2-044 blocks tumor metastasis and increases antitumor immune response. Nov 06 2020
S6901 MSAB MSAB is a selective inhibitor of Wnt/β-catenin signaling that binds to β-catenin, promoting its degradation, and specifically downregulates Wnt/β-catenin target genes. MSAB shows potent anti-tumor effects. Sep 03 2020
S8968 PRI-724 PRI-724 (C-82 prodrug, ICG-001 analog) is a potent and specific inhibitor that disrupts the interaction of β-catenin and CBP. Jul 05 2020
S0733 Tegatrabetan (BC-2059) Tegatrabetan (BC2059) is an antagonist of β-Catenin. Tegatrabetan (BC2059) treatment disrupts the binding of β-catenin with the scaffold protein transducin β-like 1 (TBL1) and proteasomal degradation and declines in the nuclear levels of β-catenin. May 09 2020
Ubiquitin
Catalog No. Product Name Information Added
E1118 SJB3-019A SJB3-019A, a potent USP1 inhibitor, is 5 times more potent than SJB2-043 in promoting inhibitor of DNA-binding-1 (ID1) degradation and cytoxicity with IC50 of 0.0781 μM in K562 cells. Jun 16 2022
E0389 DUBs-IN-2 DUBs-IN-2 is a potent inhibitor of USP7 and USP8 deubiquitinating enzymes.  May 06 2022
E1087 5-amino-2,4-dimethylpyridine (5A-DMP)

5-amino-2,4-dimethylpyridine (5A-DMP) is a novel tandem Tudor domain (TTD)-binding compound that inhibits the full-length UHRF1:LIG1 interaction in Xenopus egg extracts.

Jan 24 2022
E0351 NSC232003 NSC232003 is a highly potent and cell-permeable UHRF1 inhibitor that binds to the 5mC binding pocket of the SRA domain of UHRF1. NSC232003 modulates DNA methylation in a cellular context. Dec 22 2021
S6943 IU1-47 IU1-47 is a potent and specific inhibitor of USP14 with an IC50 of 0.6 μM. IU1-47 shows ∼33-fold selectivity for USP14 over USP5 (IsoT). Sep 10 2021
S8300 CC-885

CC-885 is a novel cereblon (CRBN) modulator. CC-885 selectively promotes CRBN- and p97-dependent PLK1 ubiquitination and degradation.

Sep 01 2021
S9832 CC-90009 CC-90009 is a novel cereblon (CRBN) E3 ligase modulator and specifically targets GSPT1 (G1 to S phase transition 1) for proteasomal degradation. Aug 19 2021
S6883 HBX 19818 HBX19818 is a specific inhibitor of USP7 with an IC 50 of 28.1 μM. Jul 23 2021
S8967 XL177A XL177A is a potent, selective and irreversible inhibitor of Ubiquitin specific peptidase 7 (USP7) with IC50 of 0.34 nM. May 24 2021
S9724 SZL P1-41 SZL P1-41 (compound #25) is a specific inhibitor of S-phase kinase-associated protein 2 (Skp2) that indeed binds to Skp2, prevents Skp2-Skp1 interaction and inhibits Skp2 SCF E3 ligase activity, which consequently suppresses survival of cancer cells and cancer stem cells. SZL P1-41 causes higher apoptosis rates in cancer cells. Apr 27 2021
Neuronal Signaling
Catalog No. Product Name Information Added
E1049 CL316243 CL316243 is a highly potent selective β3-adrenoceptor agonist with a EC50 of 3 nM, but is an extremely poor to β1/2- receptors. Jun 16 2022
S2089 Fenoldopam Fenoldopam (SKF 82526) is a selective dopamine-1 (DA1) receptor agonist with natriuretic/diuretic properties with EC50 of 55.5 nM in stimulating cAMP accumulation in LLC-PK1 cells, which is more potent than DA . Jun 16 2022
S1634 Acetaminophen Acetaminophen is a COX inhibitor for COX-1 and COX-2 with IC50 of 113.7 μM and 25.8 μM, respectively. Jun 15 2022
E1050 PEAQX PEAQX (NVP-AAM077) is an effective and orally available human NMDA antagonist, which shows preference in excess of 100-fold for hNMDA 1A/2A (IC50=of 270 nM) over hNMDA 1A/2B receptors (IC50=29,600 nM). May 26 2022
E0176 Dinotefuran

Dinotefuran (MTI-446), a neonicotinoid, is an effective nAChRs agonist with EC50 of 7.8 μM and shows high insecticidal activity on Da2b2 hybrid nAChRs.

Jan 12 2022
S2917 Cutamesine Dihydrochloride Cutamesine dihydrochloride (SA4503 dihydrochloride; AGY94806 dihydrochloride) is a potent Sigma 1 receptor agonist with an IC50 of 17.4 nM in guinea pig brain membranes. Dec 28 2021
E0172 Imidacloprid

Imidacloprid is a nicotinic acetylcholine receptor (nAChR) agonist with potent insecticidal activity.

Dec 14 2021
E0357 Eliapixant

Eliapixant (BAY1817080) is a highly potent and selective P2X3 receptor antagonist with a mean IC50 of 8 nM.

Dec 14 2021
E0164 Antazoline Phosphate

Antazoline Phosphate is the phosphate salt of antazoline. Antazoline is a first-generation antihistaminic agent and acts as a histamine H1 receptor antagonist.

Dec 14 2021
E0165 Phenelzine sulfate

Phenelzine Sulfate is a hydrazine derivative and acts as a potent non-selective monoamine oxidase (MAO) inhibitor with an IC50 of 0.9 μM.

Dec 14 2021
Others
Catalog No. Product Name Information Added
E0423 (R)-Avanafil

(R)-Avanafil is the R-enantiomer of Avanafil. Avanafil is a highly selective PDE5 inhibitor with IC50 of 5.2 nM.

Jun 24 2022
E1174 NK01-63   Jun 24 2022
E2839 Bisindolylmaleimide VIII (acetate)   Jun 24 2022
S9944 PRN1008   Jun 23 2022
E1080 HG106   Jun 23 2022
E0835 CID-1517823   Jun 23 2022
P1137 Thymulin   Jun 23 2022
S9878 PF-07104091   Jun 23 2022
P1116 Epitalon   Jun 23 2022
P1118 Dermorphin   Jun 23 2022